Owlstone Medical headed off fierce competition to take the Business Weekly 2016 AstraZeneca/MedImmune Life Science Innovation Award.
Jane Osbourn of MedImmune, said: “Owlstone’s newly-formed medical division has invented a breath test to provide much earlier diagnosis of cancer, asthma and other diseases and conditions. We were impressed by the potential of the technology to save the NHS millions, slash hospital admissions and – most importantly because of swifter diagnosis – to save lives.”
About Owlstone Medical
Owlstone Medical has developed a breathalyzer for disease.
Our Vision: Owlstone Medical will become the global leader in non-invasive diagnostics for cancer, infectious disease and inflammatory disease.
Our Mission: Save 100,000 lives and save $1.5B in health care costs by 2020. www.owlstonemedical.com #save100klives